AMILI is a precision gut microbiome company that translates microbiome science into personalized, clinically-informed solutions for gut and overall health. The company offers at-home gut microbiome test kits, targeted probiotics for immune-metabolic, brain and cognitive, and digestive health, and microbiome restoration therapy. Its Optimise Plus program combines microbiome profiling with real-time glucose response and wearable data to deliver personalized nutrition and lifestyle plans guided by dedicated nutritionists. AMILI operates Asia's largest multi-ethnic gut microbiome database with over 10,000 guts profiled and 200+ partner clinics across the region. Founded in 2019 and headquartered in Singapore, the company has raised $10.5 million in Series A funding from investors including East Ventures, Vulcan Capital, Pruksa, Emtek, SEEDS Capital, and TVM Capital Healthcare.
AMILI
Series AAMILI is a precision gut microbiome company that translates microbiome science into personalized, clinically-informed solutions for gut and overall health. The company offers at-home gut microbiome test kits, targeted probiotics for immune-metabolic, brain and cognitive, and digestive health, and microbiome restoration therapy. Its Optimise Plus program combines microbiome profiling with real-time glucose response…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Microbiomics,
Nutraceuticals Tech > Dietary Supplements > Disease Specific > Diversified
Team background
College Wise > National University of Singapore (NUS), The University of New South Wales
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.